eptacog alfa: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
eptacog alfa: clinical details
Prescribing considerations
- Initiate under clinicians experienced in haemophilia or bleeding disorders; severe postpartum haemorrhage requires multidisciplinary expertise.
- Address other contributors to bleeding, including inadequate fibrinogen or platelet count where relevant.
- Weigh benefit against thrombosis or DIC risk in atherosclerosis, coronary disease, liver disease, sepsis, crush injury, perioperative states, pregnancy, the peripartum period and neonates.
- Record the product name and batch number for biological traceability.
Contraindications and cautions
- Hypersensitivity to eptacog alfa or any excipient
- Hypersensitivity to mouse, hamster or bovine proteins
Monitoring
- Assess bleeding severity and clinical haemostatic response; PT and aPTT shortening does not reliably predict efficacy.
- In congenital factor VII deficiency, assess factor VII activity and PT where appropriate and investigate inhibitory antibodies if response is unexpectedly poor.
- Monitor clinically for thrombosis, DIC and hypersensitivity in susceptible patients.
Clinical pharmacology
Eptacog alfa is recombinant activated factor VII produced using baby hamster kidney cells. It enhances local factor X activation, thrombin generation and fibrin formation at activated platelet surfaces.
Formulation and product differences
- The selected 2 mg and 5 mg products are powder-and-solvent presentations with different vial contents.
- After reconstitution, both selected presentations contain eptacog alfa at the same concentration.
- The reconstituted solution should be colourless and free from visible particles; it must not be mixed with infusion solutions or given by intravenous drip.
eptacog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 2 mg
eptacog alfa interactions
The specialist team should review all haemostatic treatments because combining clotting products may alter safety or response.
Prothrombin complex concentrates, activated or non-activated
Concurrent use should be avoided because the interaction and thrombotic risk are uncertain.
Recombinant factor XIII
The combination is not recommended because non-clinical evidence suggests exaggerated coagulation effects.
Antifibrinolytics, including tranexamic acid or aminocaproic acid
Combined use may be considered clinically, but experience is limited and specialist oversight is required.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.